CMS Sticks To Its Original Thinking In Final VAD Coverage Decision
This article was originally published in The Gray Sheet
Executive Summary
The agency’s Oct. 31 national coverage determination for ventricular assist devices differs little from the August proposal – a result that analysts are speculating could benefit VAD maker Thoratec and potentially disadvantage HeartWare.
You may also be interested in...
CMS Fields Many Suggestions And Criticisms On Proposed VAD Policy
Several stakeholders are still pushing CMS to recognize “bridge-to-decision” heart failure patients who may eventually be suitable for a heart transplant but are not so at the time they receive a ventricular assist device.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.